{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:01:17Z","timestamp":1774947677913,"version":"3.50.1"},"reference-count":28,"publisher":"FapUNIFESP (SciELO)","issue":"0","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Sa\u00fade P\u00fablica"],"published-print":{"date-parts":[[2016]]},"abstract":"<jats:p>ABSTRACT  OBJECTIVE  To evaluate treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis who started therapies with disease-modifying antirheumatic drugs (DMARD) and tumor necrosis factor blockers (anti-TNF drugs).  METHODS  This retrospective cohort study from July 2008 to September 2013 evaluated therapy persistence, which is defined as the period between the start of treatment until it is discontinued, allowing for an interval of up to 30 days between the prescription end and the start of the next prescription. Odds ratio (OR) with 95% confidence intervals (95%CI) were calculated by logistic regression models to estimate the patients\u2019 chances of persisting in their therapies after the first and after the two first years of follow-up.  RESULTS  The study included 11,642 patients with rheumatoid arthritis \u2013 2,241 of these started on anti-TNF drugs (+\/-DMARD) and 9,401 patients started on DMARD \u2013 and 1,251 patients with ankylosing spondylitis \u2013 976 of them were started on anti-TNF drugs (+\/-DMARD) and 275 were started on DMARD. In the first year of follow-up, 63.5% of the patients persisted in their therapies with anti-TNF drugs (+\/-DMARD) and 54.1% remained using DMARD in the group with rheumatoid arthritis. In regards to ankylosing spondylitis, 79.0% of the subjects in anti-TNF (+\/-DMARD) group and 41.1% of the subjects in the DMARD group persisted with their treatments. The OR (95%CI) for therapy persistence was 1.50 (1.34-1.67) for the anti-TNF (+\/-DMARD) group as compared with the DMARD group in the first year for the patients with rheumatoid arthritis, and 2.33 (1.74-3.11) for the patients with ankylosing spondylitis. A similar trend was observed at the end of the second year.  CONCLUSIONS  A general trend of higher rates of therapy persistence with anti-TNF drugs (+\/-DMARD) was observed as compared to DMARD in the study period. We observed higher persistence rates for anti-TNF drugs (+\/-DMARD) in patients with ankylosing spondylitis as compared to rheumatoid arthritis; and a higher persistence for DMARD in patients with rheumatoid arthritis as compared to ankylosing spondylitis.<\/jats:p>","DOI":"10.1590\/s1518-8787.2016050006265","type":"journal-article","created":{"date-parts":[[2016,8,20]],"date-time":"2016-08-20T14:00:52Z","timestamp":1471701652000},"source":"Crossref","is-referenced-by-count":17,"title":["Treatment persistence in patients with rheumatoid arthritis and ankylosing spondylitis"],"prefix":"10.1590","volume":"50","author":[{"given":"Marina Amaral de \u00c1vila","family":"Machado","sequence":"first","affiliation":[{"name":"Universidade Federal de Minas Gerais,  Brasil; McGill University,  Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiano Soares de","family":"Moura","sequence":"additional","affiliation":[{"name":"McGill University,  Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Ferr\u00e9","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasha","family":"Bernatsky","sequence":"additional","affiliation":[{"name":"McGill University,  Canada; McGill University,  Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elham","family":"Rahme","sequence":"additional","affiliation":[{"name":"McGill University,  Canada; McGill University,  Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco de Assis","family":"Acurcio","sequence":"additional","affiliation":[{"name":"McGill University,  Canada; Universidade Federal de Minas Gerais,  Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"2","key":"ref1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1590\/S0102-30982009000200007","article-title":"Perfil demogr\u00e1fico e epidemiol\u00f3gico dos usu\u00e1rios de medicamentos de alto custo no Sistema \u00danico de Sa\u00fade","volume":"26","author":"Acurcio FA","year":"2009","journal-title":"Rev Bras Estud Popul"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"R439","DOI":"10.1186\/ar1693","article-title":"Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab","volume":"7","author":"Baraliakos X","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"ref3","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12325-012-0037-5","article-title":"Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings","volume":"29","author":"Bonafede M","year":"2012","journal-title":"Adv Ther"},{"issue":"9570","key":"ref4","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun J","year":"2007","journal-title":"Lancet"},{"issue":"6","key":"ref5","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun J","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jbspin.2006.06.011","article-title":"TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease","volume":"74","author":"Brocq O","year":"2007","journal-title":"Joint Bone Spine"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/ket387","article-title":"Global prevalence of ankylosing spondylitis","volume":"53","author":"Dean LE","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jbspin.2014.02.014","article-title":"Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice","volume":"81","author":"Frazier-Mironer A","year":"2014","journal-title":"Joint Bone Spine"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ard.2009.124446","article-title":"Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years\u2019 surveillance in the Danish nationwide DANBIO registry","volume":"69","author":"Glintborg B","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3346\/jkms.2014.29.9.1205","article-title":"Drug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"29","author":"Kang JH","year":"2014","journal-title":"J Korean Med Sci"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/rheumatology\/keq325","article-title":"Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register","volume":"50","author":"Kievit W","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"9285","key":"ref12","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","article-title":"Rheumatoid arthritis","volume":"358","author":"Lee DM","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/ard.2009.113308","article-title":"Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis","volume":"69","author":"Lie E","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00296-013-2772-6","article-title":"Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis","volume":"33","author":"Machado MA","year":"2013","journal-title":"Rheumatol Int"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1590\/S0034-89102010000300021","article-title":"Iniciativa STROBE: subs\u00eddios para a comunica\u00e7\u00e3o de estudos observacionais","volume":"44","author":"Malta M","year":"2010","journal-title":"Rev Saude Publica"},{"issue":"5","key":"ref16","first-page":"169","article-title":"Estudo multic\u00eantrico da preval\u00eancia da artrite reumatoide do adulto em amostras da popula\u00e7\u00e3o brasileira","volume":"33","author":"Marques Neto JF","year":"1993","journal-title":"Rev Bras Reumatol"},{"issue":"12","key":"ref17","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1093\/rheumatology\/kes217","article-title":"The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review","volume":"51","author":"Moots RJ","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"ref18","first-page":"135","article-title":"Consenso 2012 da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoide","volume":"52","author":"Mota LMH","year":"2012","journal-title":"Rev Bras Reumatol"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.clinthera.2013.09.015","article-title":"Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis","volume":"35","author":"Navarro-Mill\u00e1n I","year":"2013","journal-title":"Clin Ther"},{"issue":"12","key":"ref20","doi-asserted-by":"crossref","first-page":"867","DOI":"10.5414\/CP201707","article-title":"The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009: a retrospective analysis","volume":"50","author":"Nell-Duxneuner V","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"12","key":"ref21","article-title":"Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study","volume":"12","author":"Ogale S","year":"2011","journal-title":"BMC Musculoskelet Disord"},{"issue":"2","key":"ref22","first-page":"107","article-title":"A constru\u00e7\u00e3o da Base Nacional de Dados em Terapia Renal Substitutiva (TRS) centrada no indiv\u00edduo: relacionamento dos registros de \u00f3bitos pelo subsistema de Autoriza\u00e7\u00e3o de Procedimentos de Alta Complexidade (Apac\/SIA\/SUS) e pelo Sistema de Informa\u00e7\u00f5es sobre Mortalidade (SIM) \u2013 Brasil, 2000-2004","volume":"18","author":"Queiroz OV","year":"2009","journal-title":"Epidemiol Serv Saude"},{"issue":"4","key":"ref23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1590\/S0482-50042007000400001","article-title":"Consenso Brasileiro de Espondiloartropatias: espondilite anquilosante e artrite psori\u00e1sica diagn\u00f3stico e tratamento: primeira revis\u00e3o","volume":"47","author":"Sampaio-Barros PD","year":"2007","journal-title":"Rev Bras Reumatol"},{"issue":"6","key":"ref24","first-page":"857","article-title":"Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database","volume":"31","author":"Scir\u00e8 CA","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh JA","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"ref26","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/ard.2010.139774","article-title":"Impact of concomitant use of DMARD on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"70","author":"Soliman MM","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.rdc.2012.09.003","article-title":"Epidemiology of spondyloarthritis","volume":"38","author":"Stolwijk C","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1590\/S0482-50042011000200005","article-title":"Registro brasileiro de biol\u00f3gicos: processo de implementa\u00e7\u00e3o e resultados preliminares do BiobadaBrasil","volume":"51","author":"Titton DC","year":"2011","journal-title":"Rev Bras Reumatol"}],"container-title":["Revista de Sa\u00fade P\u00fablica"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/rsp\/v50\/0034-8910-rsp-S1518-87872016050006265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T01:27:03Z","timestamp":1495589223000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0034-89102016000100234&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":28,"journal-issue":{"issue":"0","published-print":{"date-parts":[[2016]]}},"alternative-id":["S0034-89102016000100234"],"URL":"https:\/\/doi.org\/10.1590\/s1518-8787.2016050006265","relation":{},"ISSN":["0034-8910"],"issn-type":[{"value":"0034-8910","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}